AB Science webcast – Masitinib in Sickle Cell Disease
30/11/2023 – Presentation of the Masitinib in Sickle Cell Disease webcast
AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell disease
28/11/2023 – AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
27/11/2023 – AB Science announces today that a new clinical development program for masitinib in sickle cell disease is among the 19 winning projects to be funded under the sixth call for “Hospital-University Research in Health” (Recherche Hospitalo-Universitaire en santé) projects, which part of the Future Investments Program
Revenues for the first half of 2023 and update on AB Science’s activities
29/09/2023 – AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
18/09/2023 – AB Science today provided an update on the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) timetable for examination of the masitinib marketing authorization application in amyotrophic lateral sclerosis (ALS)
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
26/06/2023 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating (mCRPC) with its lead compound masitinib, based on findings from study AB12003
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
01/06/2023 – AB Science today announced that the patent office of Canada has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib
AB Science to hold its Annual General Meeting of Shareholders on June 30, 2023
30/05/2023 – AB Science will hold its Annual General Meeting on Friday 30 June 2023 at 3.30pm
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
17/05/2023 – AB Science today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, during an Panel Discussion at the ALS Drug Development Summit in Boston, USA (May 16-18, 2023)
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
09/05/2023 – AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)